Nevertheless, in our meta-analysis, a pooled PLR of 5.85 (95% CI, 2.72-12.57) and NLR 0.22 (95% C, 0.15-0.32) indicated that patients with bladder cancer have an ~5.86-fold higher chance of testing positive using UCA1 compared with controls and 33% individuals with bladder cancer have an negative result. Here, UCA1 is linked to urinary bladder cancer.